3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.